{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000014","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.997147+00:00","generated_at":"2026-06-05T12:05:49.858538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas Q4/FY2023: revenue down 40% to $78.5M; CFO resigns, vepdegestrant Fast Track","bullets":["FY2023 revenue $78.5M vs $131.4M prior; Q4 revenue negative $43.1M. R&D expense $379.7M. Cash $1.27B, sufficient into 2027.","Vepdegestrant: FDA Fast Track; Phase 1b combo with palbociclib CBR 63%, ORR 42%, median PFS 11.1 months. Phase 3 VERITAC-2 enrollment on track for 2H 2024.","AR program: ARV-766 selected as lead; new Phase 1/2 data showed broader efficacy vs bavdegalutamide. Phase 2 PFS data mid-2024; regulatory discussions for Phase 3 in mCRPC Q2 2024.","CFO Sean Cassidy resigns effective Feb 29; interim CFO Randy Teel. Board launched permanent replacement search.","Closed $350M oversubscribed private placement; new Pfizer collaboration for E3 ligases. Regulatory clearance for ARV-102 (LRRK2) and ARV-393 (BCL6) Phase 1 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000014","json":"https://secwatch.observer/filing/0001655759-24-000014.json","markdown":"https://secwatch.observer/filing/0001655759-24-000014.md","text":"https://secwatch.observer/filing/0001655759-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/0001655759-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/arvn-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:05:49.858538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8637bb70485e526c90ba741c7d37e3c2e0816eca","claim":"ARVINAS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/0001655759-24-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}